Hernáez-Alsina Tania, Caballol-Oliva Berta, Díaz-González Álvaro, Guedes-Leal Cassia, Reig María
Servicio de Aparato Digestivo, Hospital San Pedro, Logroño, La Rioja, España; Grupo BCLC, Unidad de Oncología Hepática, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Universidad de Barcelona, Barcelona, España.
Grupo BCLC, Unidad de Oncología Hepática, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Universidad de Barcelona, Barcelona, España.
Gastroenterol Hepatol. 2019 Oct;42(8):502-511. doi: 10.1016/j.gastrohep.2019.05.003. Epub 2019 Aug 28.
Eradication of the hepatitis C virus (HCV) with interferon-free therapies (DAAs) has modified the course of the disease, as the rate of patients with compensated cirrhosis who achieve a sustained virological response exceeds 95%. However, the impact on development of hepatocellular carcinoma (HCC) is currently in dispute. This argument could be divided into different key points: the impact of DAA on rate of HCC recurrence, the temporal link between starting DAAs and HCC recurrence, and finally, the aggressive pattern of HCC. Therefore, the aim of this review is to analyse the available results in this population of patients from a clinical perspective where the risks and benefits of HCV eradication with DAA therapies are evaluated in patients with complete response of HCC.
使用无干扰素疗法（直接抗病毒药物，DAAs）根除丙型肝炎病毒（HCV）改变了疾病进程，因为实现持续病毒学应答的代偿期肝硬化患者比例超过95%。然而，目前对于其对肝细胞癌（HCC）发生发展的影响存在争议。这一争议可分为不同关键点：DAAs对HCC复发率的影响、开始使用DAAs与HCC复发之间的时间联系，以及最后HCC的侵袭模式。因此，本综述的目的是从临床角度分析该患者群体的现有结果，即在HCC完全缓解的患者中评估使用DAA疗法根除HCV的风险和益处。
